5-fluoro-6-phenyl-2,1,3-benzthiadiazole | 871512-66-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻二唑类
• 英文名称: 5-fluoro-6-phenyl-2,1,3-benzthiadiazole
• 英文别名: 5-Fluoro-6-phenyl-2,1,3-benzothiadiazole
• CAS: 871512-66-2
• 化学式: C₁₂H₇FN₂S
• 分子量: 230.265
• InChiKey: BCBFLGZTOWELTK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Ubiquitin ligase inhibitors
  申请人：Ramesh Usha

  公开号：US20050282818A1

  公开（公告）日：2005-12-22

  This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved, such as signal transduction pathways. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a compound or pharmaceutical composition according to the invention. Particularly, the compounds and pharmaceutical compositions are useful to inhibit the ubiquitin ligase activity of TRAF6.

  本发明描述了化合物和药物组合物，可用作泛素代理抑制剂，特别是泛素连接酶抑制剂。本发明的化合物和药物组合物可用作生物体中涉及泛素化的生物化学途径的抑制剂，例如信号转导途径。本发明还包括使用本发明的化合物和药物组合物治疗需要抑制泛素化的疾病的方法。此外，本发明还包括抑制细胞中泛素化的方法，其中包括将希望抑制泛素化的细胞与本发明的化合物或药物组合物接触。特别地，这些化合物和药物组合物可用于抑制TRAF6的泛素连接酶活性。
• UBIQUITIN LIGASE INHIBITORS
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP1758873A1

  公开（公告）日：2007-03-07
• [EN] UBIQUITIN LIGASE INHIBITORS<br/>[FR] INHIBITEURS DE L'UBIQUITINE LIGASE
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2006002284A1

  公开（公告）日：2006-01-05

  This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved, such as signal transduction pathways. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a compound or pharmaceutical composition according to the invention. Particularly, the compounds and pharmaceutical compositions are useful to inhibit the ubiquitin ligase activity of TRAF6.
• [EN] UBIQUITIN LIGASE INHIBITORS<br/>[FR] INHIBITEURS D'UBIQUITINE LIGASE
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2008115259A2

  公开（公告）日：2008-09-25

  [EN] This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved, such as signal transduction pathways. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a compound or pharmaceutical composition according to the invention. Particularly, the compounds and pharmaceutical compositions are useful to inhibit the ubiquitin ligase activity of TRAF6.
  [FR] L'invention concerne des composés et des compositions pharmaceutiques utiles comme inhibiteurs d'agent d'ubiquitine, en particulier des inhibiteurs d'ubiquitine ligase. Les composés et les compositions pharmaceutiques proposés par la présente invention sont utiles en tant qu'inhibiteurs des voies biochimiques d'organismes impliquant une ubiquitine, comme des voies de transduction de signal. L'invention comprend également l'utilisation des composés et des compositions pharmaceutiques de la présente invention dans le traitement d'infections requérant une inhibition d'ubiquitination. De plus, l'invention concerne des procédés d'inhibition d'ubiquitination dans une cellule, incluant la mise en contact d'une cellule dans laquelle une inhibition d'ubiquitination est souhaitée avec un composé ou une composition pharmaceutique proposés par l'invention, en particulier pour inhiber l'activité d'ubiquitine ligase de TRAF 6.